Lenvatinib/Pembrolizumab Combo Improved Efficacy Over Sunitinib Across RCC Risk Groups
June 9th 2021Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.
Numerical Boost in OS With TAK-700 Misses Threshold for Significance in mHSPC
June 9th 2021Despite failure to reach the primary end point of statistically significant overall survival benefit, TAK-700 plus androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer may be a valid treatment option for some patients.
Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder Cancer
June 9th 2021CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.
HRQOL Analysis From CLEAR Trial Further Support Pembrolizumab/Lenvatinib Combo for Frontline RCC
June 7th 2021Across 3 health-related quality of life scales, the combination of pembrolizumab plus lenvatinib had similar or better outcomes than sunitinib for patients with metastatic renal cell carcinoma receiving treatment in the frontline.
Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCC
June 5th 2021CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.
Prolonged Duration of Response With Tivozanib for RCC Revealed at Long-Term Follow-Up
June 4th 2021Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.
Elizabeth Plimack, MD, MS, on Depth of Response in from the KEYNOTE-426 Trial
June 28th 2020Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
June 9th 2020Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426.